Tag:
Latest Headlines
Since the introduction of two expensive drugs that treat hepatitis C last year, insurers have been forced to make some tough ethical decisions regarding which members can receive the medicines.
New enrollees who purchased coverage through state and federal marketplaces are more likely to use specialty medications, such as those used to treat HIV/AIDs and hepatitis C, than people enrolled in commercial health plans, Express Scripts research finds.
New hepatitis C treatments could cost at least $200 billion in the next five years, prompting insurers to ask state officials to help pick up the tab.
Press Releases
- APIC statement in support of the National Action Plan for Combating Antibiotic-Resistant Bacteria
- Asbestos Disease Awareness Organization (ADAO) Praises Senate for Passing the Bipartisan 11th Annual "National Asbestos Awareness Week" Resolution
- AMC Health and Qualcomm Collaborate to Enhance Connectivity and Virtual Care Coordination for Chronic Care Patients
- Ascension Leading in National Value-Based Care Effort
- Study Demonstrates Concern for Retained Blood Syndrome after Heart Surgery; ClearFlow Executives Comment on New Data
- More Press Releases
Sponsored Links